RIGL News

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Ongoing Global Trials and Promising Candidates Like Sovleplenib Create Strong Investment and Innovation Opportunities

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

Rigel to Present at the Jefferies Global Healthcare Conference in London

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS